Vanda Pharmaceuticals Inc.: financial analysis
Ratios worked out from 10 fiscal years of Vanda Pharmaceuticals Inc.'s statements, compared with 665 companies in Biotechnology.
Vanda Pharmaceuticals Inc. scorecard#
Passes 5 of the 20 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.8×.
- ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Biotechnology's median of 8.6×.
- ✗Free cash flow yield above 5%-46.4%Free cash flow is -46.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✓Revenue grew in the newest year8.7%Revenue up 8.7% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-5.3%-5.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-5.3%-5.3% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-3.74 vs -0.33Diluted EPS -3.74 in fiscal 2025 against -0.33 the year before (report's currency).
- ✗Net income higher than five years earlier-$220 M-$220 M in fiscal 2025 against $23 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$220 MNet income -$220 M in fiscal 2025.
- ✗Profitable in each of the last five years3 of 5Profitable in 3 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-70.0%-70.0% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-50.9%-50.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-70.0%-70.0% in fiscal 2025 against 2.5% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.39 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.33Z-score -0.33 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $220 million.
- Free cash flow was negative: -$110 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuedno
- Gross margin rosenot on file
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.41 | × 1.2 | 0.50 |
| Retained earnings to assets | -0.81 | × 1.4 | -1.13 |
| Operating income to assets | -0.31 | × 3.3 | -1.02 |
| Market value to liabilities | 1.47 | × 0.6 | 0.88 |
| Revenue to assets | 0.44 | × 1 | 0.44 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -70.0% | -20.5% | -7.2% | 2.5% | 15.7% | -60.5% | 49% | |
| Net margin | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% | -68.9% | 43% | |
| Return on equity | -50.9% | -3.5% | 0.5% | 1.2% | 6.9% | -61.0% | 58% | |
| Return on assets | -38.5% | -2.9% | 0.4% | 1.0% | 5.9% | -44.4% | 57% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 8.7% | 3.2% | -24.3% | -5.3% | 8.3% | 15.8% | 41% | |
| Revenue growth, 3 years a year | -5.3% | -9.6% | -8.1% | 3.8% | 11.6% | 12.9% | 24% | |
| Revenue growth, 5 years a year | -2.7% | -2.6% | -0.1% | 9.0% | 13.0% | 15.4% | 18% | |
| Net income growth | — | — | -60.0% | -81.1% | 42.0% | 10.1% | — | |
| Earnings per share growth | — | — | -63.6% | -81.0% | 38.1% | 7.6% | — |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.39× | 4.39× | 4.94× | 5.68× | 6.43× | 4.39× | 28% | |
| Equity share of assets | 66.9% | 82.1% | 84.0% | 83.1% | 85.0% | 64.7% | 52% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-110 M | $-16 M | $12 M | $31 M | $64 M | $-40 M | 24% | |
| Free cash flow margin | -51.1% | -8.2% | 6.5% | 12.3% | 23.7% | -61.5% | 52% | |
| Cash conversion | — | — | 510.0% | 509.2% | 193.7% | 72.6% | — | |
| Capital spending share of revenue | 0.5% | 0.3% | 0.2% | 0.3% | 0.2% | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.38× | 0.30× | 0.30× | 0.41× | 0.48× | 0.26× | 60% |
How each figure is worked out#
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).